Secondary hyperparathyroidism

Evocalcet

Evocalcet is an oral calcimimetic agent that aims to address the gastrointestinal issues related to oral cinacalcet. A head-to-head comparison of evocalcet with cinacalcet in haemodialysis patients with secondary hyperparathyroidism showed that evocalcet is non-inferior to cinacalcet and there were fewer gastrointestinal-related adverse events.[102]Fukagawa M, Shimazaki R, Akizawa T, et al. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2018 Oct;94(4):818-25. https://www.kidney-international.org/article/S0085-2538(18)30387-9/fulltext http://www.ncbi.nlm.nih.gov/pubmed/30049473?tool=bestpractice.com ​ Evocalcet is currently only approved in Japan.